UroToday.com· @urotoday · X·· 6 hours agoScore45
Body · original
HRQoL After Induction Ipilimumab + Nivolumab and Bladder-Sparing Chemoradiotherapy in #MIBC: Phase 2 INDIBLADE Trial. Presented by Jan-Jaap Mellema @NKI_nl. #ESMO26 written coverage by @zklaassen_md > https://bit.ly/4yMMinJ #BladderCancer #Immunotherapy @myESMO
86 views · 2 likes · 1 repost · 0 replies
Conference abstracts
Emotional distress (ED) upfront neoadjuvant ipilimumab + nivolumab (IPI+NIVO) is associated with lower pathological response and toxicity
https://esmocongress.esmo.orgSource: UroToday.com · x.com
